Molecular Partners (OTCMKTS:MLLCF) Stock Price Down 32.9% – Here’s What Happened

Molecular Partners AG (OTCMKTS:MLLCF)’s share price dropped 32.9% on Monday . The company traded as low as $2.35 and last traded at $2.35. Approximately 4,093 shares were traded during mid-day trading, an increase of 78% from the average daily volume of 2,296 shares. The stock had previously closed at $3.50.

Molecular Partners Price Performance

The stock’s fifty day moving average is $3.61 and its 200 day moving average is $3.77.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.

Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.